Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBIT (2016 - 2021)

Historic EBIT for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to -$23.1 million.

  • Avadel Pharmaceuticals' EBIT fell 6224.4% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 157112.64%. This contributed to the annual value of -$85.5 million for FY2021, which is 157112.64% down from last year.
  • Per Avadel Pharmaceuticals' latest filing, its EBIT stood at -$23.1 million for Q4 2021, which was down 6224.4% from -$25.7 million recorded in Q3 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' EBIT peaked at $40.3 million during Q2 2020, and registered a low of -$75.4 million during Q4 2018.
  • Moreover, its 5-year median value for EBIT was -$7.8 million (2019), whereas its average is -$6.0 million.
  • In the last 5 years, Avadel Pharmaceuticals' EBIT plummeted by 174855.39% in 2018 and then soared by 100471.8% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' EBIT (Quarter) stood at -$4.1 million in 2017, then crashed by 1748.55% to -$75.4 million in 2018, then surged by 90.26% to -$7.3 million in 2019, then plummeted by 94.09% to -$14.3 million in 2020, then tumbled by 62.24% to -$23.1 million in 2021.
  • Its EBIT stands at -$23.1 million for Q4 2021, versus -$25.7 million for Q3 2021 and -$21.9 million for Q2 2021.